ANTABIO Raises €25 Million in Series B Financing

The financing will be used to support the clinical development of a next generation antibacterial combination

14-Dec-2023 - Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, announced that it has raised €25m in a series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors ...

Obulytix is developing a revolutionary solution for antibiotic resistance

Spin-off has built a platform that creates new ways to tackle bacterial infections

11-Dec-2023 - Obulytix, a groundbreaking biotech spin-off founded by seasoned experts in phage lysin research from Ghent University and KU Leuven, is set to revolutionize the fight against antimicrobial resistance with its novel phage lysin-based antibiotics. The innovative, phage lysin-based platform – ...

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

Spin-out from the Universities of Glasgow and Oxford

21-Nov-2023 - Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use ...

New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance

By optimizing nature’s defenders, the team has produced unprecedented phage treatments

29-Jun-2023 - The new biotech venturePHIOGENis a spin-off company fromBaylor College of Medicine’sTAILOR Labs, one of the United States only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages, viruses that infect and destroy bacteria. The company made its ...

Novel antibiotics in the fight against antimicrobial resistance

SANTERO announces a €8 million Series A funding round led by Newton Biocapital

12-Jun-2023 - Newton Biocapital (NBC), a venture capital firm focused on investing and growing early-stage life sciences companies in Europe and Japan targeting chronic health conditions, has announced the closing of a successful €8 million Series A financing round for Santero. SANTERO, a spin-off company of ...

Phage therapy diagnostic platform in global fight against multidrug-resistant infections

Vésale Bioscience receives €1.8M grant from European Innovation Council for PhageDiag project

23-Jan-2023 - Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, announces it has received €1.8M ($1.9M) in grants fromthe European Innovation Council (EIC) Accelerator Fund for its PhageDiag project, a phagogram using ...

Three partners committed to combat AMR

Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

07-Jul-2022 - Evotec SE, Boehringer Ingelheim and bioMérieux announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best ...

ArrePath raised $20 million

Seed financing to advance its machine learning-based platform for discovery of novel anti-infectives addressing antimicrobial resistance

16-Mar-2022 - ArrePath, an anti-infective drug discovery start-up addressing the global health challenge of drug resistant infections, announced that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives ...

Centauri Therapeutics closes £24 million GBP Series A investment round

Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates

23-Feb-2022 - Centauri Therapeutics Limited, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announced the close of its £24 million GBP (c. 32 million USD) Series A investment round. The funds will support the continued advancement of the ...

New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance

05-Aug-2019 - Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterialagents: Gram-Negative Antibacterials NOW (“GNA NOW”). The new GNA NOW project, led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), will work ...